• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Study identifies clinical predictors of patient satisfaction with CCH for Peyronie’s disease

News
Article

At 5 years from CCH injection, curvature and plaque volume were associated with patient satisfaction in the treatment of their Peyronie’s disease.

With nearly half of patients being satisfied 5 years after their last collagenase clostridium histolyticum (CCH) injection to treat Peyronie’s disease, certain predictors may enable urologists to counsel patient expectations, according to a retrospective study presented at the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America.1

“Nearly half of our cohort remain satisfied with their CCH therapy approximately 5 years from their last injection,” Jeffrey Song, Baylor College of Medicine, said during the presentation. “And in all, these findings can be utilized to better proactively counsel and manage patient expectations regarding their potential CCH outcomes.”

“Nearly half of our cohort remain satisfied with their CCH therapy approximately 5 years from their last injection,” Jeffrey Song, Baylor College of Medicine, said during the presentation. “And in all, these findings can be utilized to better proactively counsel and manage patient expectations regarding their potential CCH outcomes.”

“In our data, we found that final curvature and plaque volume after CCH treatment were more important to patients than the degree of change that they exhibited with their treatment,” Jeffrey Song, Baylor College of Medicine, said during the presentation.

CCH–the only FDA-approved medication for Peyronie’s disease–has demonstrated a satisfaction rate among men of about 67% within 2 years of treatment.2 However, there's very little literature regarding clinical predictors of this long-term satisfaction, according to Song.

Therefore, the retrospective chart review aimed to identify clinical predictors of long-term satisfaction with CCH for Peyronie’s disease using a standardized questionnaire (Treatment Satisfaction Questionnaire for Medication [TSQM]), from 2009 to 2022, to determine satisfaction with effectiveness, side effects, convenience, and global satisfaction.

Surveys were completed by 80 men after a median of 5.1 years (range, 2.4-6.7) after their last CCH injection.

Overall, 34 patients (42.5%) reported satisfaction with CCH treatment.

Age at presentation (mean, 59.4 years; P = 004), at last injection (mean, 60.7; P = .003), and at survey completion (mean, 65.4 years; P = .002) were significantly correlated with satisfaction with side effects.

When evaluating objective disease parameters, like curvature degree, plaque diameter, and plaque volume measurements before CCH treatment, as well as the degree of change in these parameters, were not significantly associated with satisfaction scores, Song said. However, the final measurements of curvature degree were significantly associated with effectiveness (P = .007), global satisfaction (P = .006), and TSQM total (P = .006), while final measurements of plaque volume were also associated with TSQM total (P = .04) after completion of CCH therapy.

An additional factor of interest included depression, reported by 13% of patients, which was associated with decreased patient satisfaction with effectiveness (P = .03), global satisfaction (P = .03), and TQSM total (P= .04), compared with patients who did not report with depression.

Further, roughly 13% of patients proceeded to surgery, and reported significantly decreased scores in effectiveness (P = .008) and TQSM total (P = .001).

“Nearly half of our cohort remain satisfied with their CCH therapy approximately 5 years from their last injection,” Song concluded. “And in all, these findings can be utilized to better proactively counsel and manage patient expectations regarding their potential CCH outcomes.”

References

1. Song J, Dai M, Naeem, T, Saffati G, Khera M, Lipshultz L. Clinical Predictors of Long-Term Satisfaction with Treatment of Collagenase Clostridium Histolyticum for Patients with Peyronie’s Disease. Presented at: 24th Annual Fall Scientific Meeting SMSNA; November 16-18, 2023; San Diego, CA. Abstract 118.

2. Anaissie J, Yafi FA, Traore EJ, et al. Survey of Patients and Partner Satisfaction Following Collagenase Clostridium Histolyticum Treatment for Peyronie’s Disease. Andrology. 2017;5(2):274-277. doi:10.1111/andr.12302.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.